Bryn Mawr Capital Management LLC Sells 2,929 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Bryn Mawr Capital Management LLC lowered its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 49,283 shares of the medical equipment provider’s stock after selling 2,929 shares during the quarter. Bryn Mawr Capital Management LLC’s holdings in Zimmer Biomet were worth $5,206,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Stonebridge Financial Group LLC bought a new stake in shares of Zimmer Biomet in the fourth quarter worth about $25,000. Dunhill Financial LLC grew its position in shares of Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 218 shares during the last quarter. Ashton Thomas Securities LLC purchased a new position in shares of Zimmer Biomet during the third quarter valued at approximately $28,000. Brooklyn Investment Group bought a new position in shares of Zimmer Biomet during the third quarter valued at approximately $35,000. Finally, Kentucky Trust Co purchased a new stake in Zimmer Biomet in the fourth quarter worth $39,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 1.5 %

Shares of NYSE:ZBH opened at $107.54 on Wednesday. The stock’s 50-day simple moving average is $105.83 and its two-hundred day simple moving average is $107.44. The stock has a market capitalization of $21.41 billion, a price-to-earnings ratio of 24.17, a PEG ratio of 1.95 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 52-week low of $97.69 and a 52-week high of $133.90. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the prior year, the business earned $2.20 EPS. Analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were paid a $0.24 dividend. The ex-dividend date was Monday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.89%. Zimmer Biomet’s dividend payout ratio (DPR) is 21.57%.

Analysts Set New Price Targets

Several research analysts have commented on the stock. JMP Securities restated a “market outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 7th. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Barclays cut their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research report on Monday, February 10th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Truist Financial restated a “hold” rating and set a $113.00 price target (down from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus price target of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.